Introduction/Background ErbB receptors are trans-membrane glycoproteins with tyrosine kinase activity. Especially in cancer, they are implicated in cell proliferation, transformation, angiogenesis, migration and invasion. The expression of ErbB receptors, has not been studied well in endometrial cancer patients. The main aim of our study was to investigate ErbB receptors profile in selected patients with type II endometrial cancer.

Methodology We evaluated retrospectively tissue specimens from 10 patients with type II endometrial cancer, that have been treated in the Division of Gynaecological Oncology of the University of Patras. For ErbB receptors immunostaining, we used: anti-EGFR polyclonal antibody sc-03 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) in a dilution 1:20, anti-ErbB-2 monoclonal antibody CB11 (BioGenex Laboratories Inc., San Ramon, CA, USA) in a dilution 1:100, anti-ErbB-3 polyclonal antibody sc-285 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) in a dilution 1:100 and anti-ErbB-4 polyclonal antibody sc-283 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) in a dilution 1:200.

Results For EGFR receptor, 5 cases were positive (50%) and 5 cases were negative (50%), while for ErbB-2 receptor 9 cases were positive (90%) and 1 case was negative (10%). For ErbB-3 receptor all cases were positive (100%), while for ErbB-4 receptor 7 cases were positive (70%) and 3 cases were negative (30%).

Overall, we observed high expression levels of all ErbB receptors in our study population and 5 patients were positive (50%) for all ErbB receptors.

Conclusion The high expression levels of ErbB receptors in patients with type II endometrial cancer possibly indicates a future role of ErbB-targeted therapies in well-defined subgroups of type II endometrial cancer patients with EGFR and ErbB-2 overexpression.

Disclosure Nothing to disclose.